605507 国邦医药
已收盘 09-30 15:00:00
资讯
新帖
简况
国邦医药(605507)披露全资子公司获得新兽药注册证书公告,9月29日股价下跌2.46%
证券之星 · 09-29
国邦医药(605507)披露全资子公司获得新兽药注册证书公告,9月29日股价下跌2.46%
国邦医药最新公告:全资子公司获氟雷拉纳新兽药注册证书
证券之星 · 09-29
国邦医药最新公告:全资子公司获氟雷拉纳新兽药注册证书
【机构调研记录】鹏华基金调研国邦医药、中无人机等3只个股(附名单)
证券之星 · 09-23
【机构调研记录】鹏华基金调研国邦医药、中无人机等3只个股(附名单)
股市必读:国邦医药(605507)9月22日披露最新机构调研信息
证券之星 · 09-23
股市必读:国邦医药(605507)9月22日披露最新机构调研信息
国邦医药与阿里云达成战略合作
同花顺 · 09-22
国邦医药与阿里云达成战略合作
每周股票复盘:国邦医药(605507)氟苯尼考出货量超2500吨
证券之星 · 09-20
每周股票复盘:国邦医药(605507)氟苯尼考出货量超2500吨
9月18日国邦医药涨5.03%,鹏华优质治理LOF基金重仓该股
证券之星 · 09-18
9月18日国邦医药涨5.03%,鹏华优质治理LOF基金重仓该股
国邦医药涨5.03%,西南证券一个月前给出“买入”评级
证券之星 · 09-18
国邦医药涨5.03%,西南证券一个月前给出“买入”评级
9月15日国邦医药创60日新高,鹏华优质治理LOF基金重仓该股
证券之星 · 09-15
9月15日国邦医药创60日新高,鹏华优质治理LOF基金重仓该股
国邦医药创60日新高,西南证券一个月前给出“买入”评级
证券之星 · 09-15
国邦医药创60日新高,西南证券一个月前给出“买入”评级
每周股票复盘:国邦医药(605507)将召开2026年半年度业绩说明会
证券之星 · 09-13
每周股票复盘:国邦医药(605507)将召开2026年半年度业绩说明会
国邦医药(605507)披露2026年半年度业绩说明会安排,9月10日股价上涨2.23%
证券之星 · 09-10
国邦医药(605507)披露2026年半年度业绩说明会安排,9月10日股价上涨2.23%
每周股票复盘:国邦医药(605507)累计回购1.45%股份
证券之星 · 09-06
每周股票复盘:国邦医药(605507)累计回购1.45%股份
股市必读:国邦医药新发布《国邦医药关于股份回购进展公告》
证券之星 · 09-03
股市必读:国邦医药新发布《国邦医药关于股份回购进展公告》
国邦医药(605507)披露股份回购进展公告,9月1日股价上涨2.8%
证券之星 · 09-01
国邦医药(605507)披露股份回购进展公告,9月1日股价上涨2.8%
每周股票复盘:国邦医药(605507)回购股份1.43%耗资1.72亿
证券之星 · 08-09
每周股票复盘:国邦医药(605507)回购股份1.43%耗资1.72亿
8月7日国邦医药涨5.40%,鹏华优质治理LOF基金重仓该股
证券之星 · 08-07
8月7日国邦医药涨5.40%,鹏华优质治理LOF基金重仓该股
国邦医药涨5.40%,西南证券二日前给出“买入”评级
证券之星 · 08-07
国邦医药涨5.40%,西南证券二日前给出“买入”评级
西南证券:给予国邦医药买入评级
证券之星 · 08-05
西南证券:给予国邦医药买入评级
股市必读:国邦医药新发布《2026-032 国邦医药关于股份回购进展公告》
证券之星 · 08-05
股市必读:国邦医药新发布《2026-032 国邦医药关于股份回购进展公告》
加载更多
公司概况
公司名称:
国邦医药集团股份有限公司
所属行业:
医药制造业
上市日期:
2021-08-02
主营业务:
国邦医药集团股份有限公司的主营业务是医药原料药和制剂、关键医药中间体、动物保健品的研发、生产与销售。公司的主要产品是抗生素类药、心血管系统类药、呼吸系统类药、泌尿系统类药、抗肿瘤类药、还原剂系列产品、高级胺系列产品、兽用抗生素类动保原料药产品、兽用抗虫杀虫药类动保原料药产品、马波沙星、沙拉沙星、地克珠利、环丙氨嗪、加米霉素。公司先后荣获“中国化学制药行业工业企业综合实力百强企业”、全国工商联医药业商会“中国医药工业百强企业”、“优秀院士专家工作站”、第一批浙江省制造业单项冠军企业等荣誉称号。
发行价格:
32.57
{"stockData":{"symbol":"605507","market":"SH","secType":"STK","nameCN":"国邦医药","latestPrice":18.09,"timestamp":1790751600000,"preClose":17.87,"halted":0,"volume":5611820,"delay":0,"changeRate":0.0123,"floatShares":782000000,"shares":782000000,"eps":0.9032,"marketStatus":"已收盘","change":0.22,"latestTime":"09-30 15:00:00","open":17.9,"high":18.31,"low":17.87,"amount":102000000,"amplitude":0.0246,"askPrice":18.09,"askSize":65,"bidPrice":18.08,"bidSize":15,"shortable":0,"etf":0,"ttmEps":0.9032,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":17.87,"symbolType":"stock","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":19.66,"lowLimit":16.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":782352900,"isCdr":false,"pbRate":1.69,"roa":"--","peRate":20.028787,"roe":"3.96%","epsLYR":1.48,"committee":0.12156,"marketValue":14153000000,"turnoverRate":0.0072,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-10-08。","floatMarketCap":14153000000},"requestUrl":"/m/hq/s/605507","defaultTab":"news","newsList":[{"id":"2671716210","title":"国邦医药(605507)披露全资子公司获得新兽药注册证书公告,9月29日股价下跌2.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671716210","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671716210?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:09","pubTimestamp":1790690962,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘,国邦医药报收于17.87元,较前一交易日下跌2.46%,最新总市值为139.81亿元。近日,国邦医药发布关于全资子公司获得新兽药注册证书的公告。公告显示,公司全资子公司浙江国邦药业有限公司与其他单位联合申报的“氟雷拉纳”获农业农村部核发新兽药注册证书,该药品为二类新兽药,监测期4年,用于犬、猫体外寄生虫防治。产品上市前尚需取得兽药产品批准文号。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900039812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671329018","title":"国邦医药最新公告:全资子公司获氟雷拉纳新兽药注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2671329018","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671329018?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:27","pubTimestamp":1790674050,"startTime":"0","endTime":"0","summary":"国邦医药(605507.SH)公告称,公司全资子公司浙江国邦与其他单位联合申报的“氟雷拉纳”获农业农村部批准为新兽药,类别为二类,监测期4年。该原料药主要用于配制犬、猫用体外寄生虫防治制剂,有助于丰富公司宠物用原料药产品结构,推动国产替代。产品上市前仍需取得兽药产品批准文号。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900028491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669736951","title":"【机构调研记录】鹏华基金调研国邦医药、中无人机等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669736951","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669736951?lang=zh_cn&edition=full","pubTime":"2026-09-23 08:09","pubTimestamp":1790122172,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及9月22日披露的机构调研信息,鹏华基金近期对3家上市公司进行了调研,相关名单如下:1)国邦医药 调研纪要:硼氢化钠是危险化学品,生产技术壁垒高,公司是国内少数可大规模稳定供应的企业之一,广泛应用于医药、农药、电子等领域,并与CDMO药企合作。其为氟苯尼考生产的关键原料,当前订单饱满,价格因成本与供给紧张已上涨,预计四季度延续趋紧态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300007318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0279","BK0239","688297","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669012915","title":"股市必读:国邦医药(605507)9月22日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2669012915","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669012915?lang=zh_cn&edition=full","pubTime":"2026-09-23 01:52","pubTimestamp":1790099536,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘,国邦医药报收于18.26元,上涨1.16%,换手率1.67%,成交量13.03万手,成交额2.34亿元。硼氢化钠是氟苯尼考生产的关键原料之一,当前为市场性价比最优还原剂。动保板块上半年实现收入13.53亿元,占总收入43.04%;公司拥有19个国内注册获批动保原料药品种;氟苯尼考经历长期不合理低价后行业利润承压,集中度提升,近期价格回暖,四季度景气度预期乐观。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300002363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142103","title":"国邦医药与阿里云达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142103","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669142103?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:37","pubTimestamp":1790069820,"startTime":"0","endTime":"0","summary":"人民财讯9月22日电,9月22日,以“智以致用”为主题的2026云栖大会在杭州国际博览中心启幕,国邦医药集团与阿里云宣布达成战略合作。接下来,国邦医药将与阿里云深化协同,围绕组织变革、营 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260922/c680176106.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260922/c680176106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668906789","title":"每周股票复盘:国邦医药(605507)氟苯尼考出货量超2500吨","url":"https://stock-news.laohu8.com/highlight/detail?id=2668906789","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668906789?lang=zh_cn&edition=full","pubTime":"2026-09-20 01:30","pubTimestamp":1789839034,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘,国邦医药报收于18.17元,较上周的15.69元上涨15.81%。本周共计1次涨停收盘,无跌停收盘情况。问:公司最近主要产品,比如硼钾硼钠、氟苯尼考、强力霉素的量价变化情况答:近期硼氢化钠、硼氢化钾新增订单有所增加,氟苯尼考上半年出货量超2500吨,市占率稳居全球前列。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668949221","title":"9月18日国邦医药涨5.03%,鹏华优质治理LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668949221","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668949221?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:40","pubTimestamp":1789720805,"startTime":"0","endTime":"0","summary":"证券之星消息,9月18日国邦医药涨5.03%创60日新高,收盘报18.17元,换手率2.31%,成交量18.05万手,成交额3.24亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共6家,其中持有数量最多的公募基金为鹏华基金的鹏华优质治理LOF。鹏华优质治理LOF目前规模为8.55亿元,最新净值1.2683,较上一交易日上涨0.38%,近一年下跌7.77%。鹏华优质治理LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800025770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668949271","title":"国邦医药涨5.03%,西南证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2668949271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668949271?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:39","pubTimestamp":1789720793,"startTime":"0","endTime":"0","summary":"今日国邦医药涨5.03%,收盘报18.17元。2026年8月5日,西南证券研究员徐卿,赵磐发布了对国邦医药的研报《2026年中报点评:营收稳健增长,利润短期承压,动保与创新驱动新引擎显现》,该研报对国邦医药给出“买入”评级。研报中预计2026-2028年EPS分别为1.23元、1.52元、1.75元,对应动态PE分别为13/11/9倍,维持“买入”评级。国邦医药个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800025767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","600369"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667610701","title":"9月15日国邦医药创60日新高,鹏华优质治理LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667610701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667610701?lang=zh_cn&edition=full","pubTime":"2026-09-15 16:42","pubTimestamp":1789461730,"startTime":"0","endTime":"0","summary":"证券之星消息,9月15日国邦医药涨9.99%创60日新高,收盘报17.73元,换手率3.51%,成交量27.43万手,成交额4.74亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共6家,其中持有数量最多的公募基金为鹏华基金的鹏华优质治理LOF。鹏华优质治理LOF目前规模为8.55亿元,最新净值1.2701,较上一交易日上涨0.87%,近一年下跌7.33%。鹏华优质治理LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500026617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667610033","title":"国邦医药创60日新高,西南证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667610033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667610033?lang=zh_cn&edition=full","pubTime":"2026-09-15 16:41","pubTimestamp":1789461717,"startTime":"0","endTime":"0","summary":"今日国邦医药创60日新高,收盘报17.73元。2026年8月5日,西南证券研究员徐卿,赵磐发布了对国邦医药的研报《2026年中报点评:营收稳健增长,利润短期承压,动保与创新驱动新引擎显现》,该研报对国邦医药给出“买入”评级。研报中预计2026-2028年EPS分别为1.23元、1.52元、1.75元,对应动态PE分别为13/11/9倍,维持“买入”评级。国邦医药个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500026609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667500614","title":"每周股票复盘:国邦医药(605507)将召开2026年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667500614","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667500614?lang=zh_cn&edition=full","pubTime":"2026-09-13 03:24","pubTimestamp":1789241054,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘,国邦医药报收于15.69元,较上周的15.58元上涨0.71%。本周,国邦医药9月11日盘中最高价报16.17元。本周关注点公司公告汇总:国邦医药将于2026年09月17日召开2026年半年度业绩说明会。公司公告汇总国邦医药集团股份有限公司将于2026年09月17日13:00-14:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会,介绍公司经营成果及财务状况。会后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300001040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666564570","title":"国邦医药(605507)披露2026年半年度业绩说明会安排,9月10日股价上涨2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666564570","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666564570?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:44","pubTimestamp":1789033463,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘,国邦医药报收于16.04元,较前一交易日上涨2.23%,最新总市值为125.49亿元。该股当日开盘15.72元,最高16.06元,最低15.51元,成交额达7982.08万元,换手率为0.64%。公告显示,国邦医药集团股份有限公司将于2026年09月17日13:00-14:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会,介绍公司经营成果及财务状况。投资者可于2026年09月10日至09月16日16:00前通过上证路演中心网站或公司邮箱info@gbgcn.com提交问题。会后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000031999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665366591","title":"每周股票复盘:国邦医药(605507)累计回购1.45%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2665366591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665366591?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:32","pubTimestamp":1788636732,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,国邦医药报收于15.58元,较上周的15.32元上涨1.7%。本周,国邦医药9月4日盘中最高价报15.71元。国邦医药当前最新总市值121.89亿元,在化学制药板块市值排名37/149,在两市A股市值排名1516/5214。截至2026年8月31日,公司已累计回购股份11,372,116股,占总股本的1.45%,回购最高价为16.27元/股,最低价为14.35元/股,已支付总金额175,111,913.45元。上述回购进展符合相关规定及方案要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664195845","title":"股市必读:国邦医药新发布《国邦医药关于股份回购进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664195845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664195845?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:13","pubTimestamp":1788372791,"startTime":"0","endTime":"0","summary":"公司公告汇总:截至2026年8月31日,国邦医药已累计回购股份11,372,116股,占总股本1.45%,支付金额175,111,913.45元。公司公告汇总国邦医药关于股份回购进展公告国邦医药集团股份有限公司于2026年5月29日召开董事会,审议通过以集中竞价交易方式回购股份的方案,回购资金总额为1亿元至2亿元,用于员工持股计划或股权激励,回购价格不超过23元/股,实施期限为2026年5月30日至2027年5月29日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664574348","title":"国邦医药(605507)披露股份回购进展公告,9月1日股价上涨2.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664574348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664574348?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:48","pubTimestamp":1788274095,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘,国邦医药报收于15.44元,较前一交易日上涨2.8%,最新总市值为120.8亿元。该股当日开盘14.99元,最高15.52元,最低14.95元,成交额达9144.05万元,换手率为0.76%。近日,国邦医药发布《关于股份回购进展公告》。上述回购进展符合相关规定及方案要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658673435","title":"每周股票复盘:国邦医药(605507)回购股份1.43%耗资1.72亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673435?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:40","pubTimestamp":1786210822,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,国邦医药报收于16.2元,较上周的16.24元下跌0.25%。本周,国邦医药8月3日盘中最高价报16.39元。国邦医药当前最新总市值126.74亿元,在化学制药板块市值排名39/149,在两市A股市值排名1487/5205。本周关注点公司公告汇总:国邦医药已回购股份11,183,416股,占总股本的1.43%,支付金额172,287,559.45元。上述回购进展符合相关规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657615764","title":"8月7日国邦医药涨5.40%,鹏华优质治理LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657615764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657615764?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:38","pubTimestamp":1786091923,"startTime":"0","endTime":"0","summary":"证券之星消息,8月7日国邦医药涨5.40%,收盘报16.2元,换手率2.02%,成交量15.84万手,成交额2.53亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共6家,其中持有数量最多的公募基金为鹏华基金的鹏华优质治理LOF。鹏华优质治理LOF目前规模为8.55亿元,最新净值1.2994,较上一交易日下跌0.6%,近一年上涨3.62%。鹏华优质治理LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657061571","title":"国邦医药涨5.40%,西南证券二日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2657061571","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657061571?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:38","pubTimestamp":1786091909,"startTime":"0","endTime":"0","summary":"今日国邦医药涨5.40%,收盘报16.2元。2026年8月5日,西南证券研究员徐卿,赵磐发布了对国邦医药的研报《2026年中报点评:营收稳健增长,利润短期承压,动保与创新驱动新引擎显现》,该研报对国邦医药给出“买入”评级。研报中预计2026-2028年EPS分别为1.23元、1.52元、1.75元,对应动态PE分别为13/11/9倍,维持“买入”评级。国邦医药个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547389","title":"西南证券:给予国邦医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547389","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657547389?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:55","pubTimestamp":1785934518,"startTime":"0","endTime":"0","summary":"西南证券股份有限公司徐卿,赵磐近期对国邦医药进行研究并发布了研究报告《2026年中报点评:营收稳健增长,利润短期承压,动保与创新驱动新引擎显现》,给予国邦医药买入评级。最新盈利预测明细如下:该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家;过去90天内机构目标均价为21.0。本文数据来源于西南证券股份有限公司,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500041458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","605507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657637565","title":"股市必读:国邦医药新发布《2026-032 国邦医药关于股份回购进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657637565?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:46","pubTimestamp":1785869172,"startTime":"0","endTime":"0","summary":"公司公告汇总:截至2026年7月31日,国邦医药已累计回购股份11,183,416股,占总股本1.43%,支付金额172,287,559.45元。公司公告汇总2026-032 国邦医药关于股份回购进展公告国邦医药集团股份有限公司于2026年5月29日召开董事会,审议通过以集中竞价交易方式回购股份的方案,回购资金总额为1亿元至2亿元,回购价格不超过23元/股,回购期限为2026年5月30日至2027年5月29日,用途为员工持股计划或股权激励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791205819636,"stockEarnings":[{"period":"1week","weight":-0.0393},{"period":"1month","weight":0.2044},{"period":"3month","weight":0.1537},{"period":"6month","weight":0.0234},{"period":"1year","weight":0.1413},{"period":"ytd","weight":0.0502}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"国邦医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20855人(较上一季度增加3.89%)","perCapita":"37513股","listingDate":"2021-08-02","address":"浙江省绍兴市新昌县省级高新技术产业园区兴梅大道60号","registeredCapital":"78235万元","survey":" 国邦医药集团股份有限公司的主营业务是医药原料药和制剂、关键医药中间体、动物保健品的研发、生产与销售。公司的主要产品是抗生素类药、心血管系统类药、呼吸系统类药、泌尿系统类药、抗肿瘤类药、还原剂系列产品、高级胺系列产品、兽用抗生素类动保原料药产品、兽用抗虫杀虫药类动保原料药产品、马波沙星、沙拉沙星、地克珠利、环丙氨嗪、加米霉素。公司先后荣获“中国化学制药行业工业企业综合实力百强企业”、全国工商联医药业商会“中国医药工业百强企业”、“优秀院士专家工作站”、第一批浙江省制造业单项冠军企业等荣誉称号。","listedPrice":32.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国邦医药(605507)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国邦医药(605507)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国邦医药,605507,国邦医药股票,国邦医药股票老虎,国邦医药股票老虎国际,国邦医药行情,国邦医药股票行情,国邦医药股价,国邦医药股市,国邦医药股票价格,国邦医药股票交易,国邦医药股票购买,国邦医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国邦医药(605507)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国邦医药(605507)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}